Medical Device Global Market Access

Pure Global

Navigate every market. Accelerate every launch. Medical Device Global Market Access by Pure Global is the audio briefing that turns the world’s most confusing regulatory pathways into clear, actionable roadmaps. If you’re a MedTech founder, RA/QA leader, product manager, or investor who needs to get devices cleared anywhere from Austin to Abu Dhabi, this show is your shortcut. Why listen? • Step-by-step playbooks – We decode EU MDR, U.S. 510(k), Brazil’s ANVISA, China’s NMPA, and 25 + other regimes, showing exactly how long each milestone really takes and where companies get stuck. • First-hand war stories – Hear candid interviews with regulatory veterans who have shepherded implants, software, wearables, diagnostics, and AI algorithms to market—and lived to tell the tale. • Real-time intelligence – Every episode covering the week’s new guidances, standards, and enforcement trends so you’re always ahead of the curve. • Actionable templates – From clinical evaluation checklists to technical-file skeletons, we break down the documents you’ll need and the pitfalls reviewers love to flag. • AI-powered insights – Because Pure Global mines millions of public filings, tenders, and recalls, we surface data-backed best practices you won’t hear at conferences—or from competitors. What you’ll hear • Launching SaMD under multiple risk classes in parallel • Surviving an unannounced ISO 13485 audit • Building a “reg-first” QMS that scales • Mastering Latin-American registrations without endless language cycles • Leveraging real-world evidence to shorten clinical timelines • Aligning cybersecurity, privacy, and post-market surveillance rules across regions Whether you’re plotting first entry, managing lifecycle expansions, or rescuing a delayed submission, subscribing could shave months—and millions—off your path to revenue. ⸻ Brought to you by Pure Global – the AI-native consultancy that already guides MedTech innovators through regulatory and market-access hurdles in 30 + countries. Ready for expert help on your next submission? Visit https://pureglobal.com or email info@pureglobal.com to start accelerating today.

  1. 13時間前

    Australia TGA Consultation on Medical Device Information Sharing: What Sponsors Need to Know

    Australia's Therapeutic Goods Administration (TGA) has launched a consultation on proposals to increase the public sharing of medical device information. This episode breaks down the TGA's initiative, which was announced on August 13, 2026, and explores its potential impact on manufacturers and sponsors. We discuss the types of information that may become public, the implications for post-market surveillance and data management, and the crucial feedback deadline of October 2, 2026. Learn the practical steps your team should take now to prepare for a future of greater transparency in the Australian market. Key Questions: - What specific information does the TGA propose to make public about medical devices? - How will these changes impact the obligations of Australian sponsors and manufacturers? - What is the deadline for providing feedback on this important TGA consultation? - How could increased transparency affect post-market surveillance and reporting requirements? - What steps should regulatory teams take now to prepare for these potential changes? - Will commercially sensitive information be protected under the new proposals? - How does this Australian initiative align with global trends in medical device transparency? - What are the TGA's stated goals for improving the sharing of medical device information? Sources: - https://www.tga.gov.au/news/news/consultation-improving-sharing-information-about-medical-devices - https://www.tga.gov.au/resources/consultations/consultation-sharing-more-information-about-medical-devices How Pure Global can help: Pure Global helps MedTech and IVD companies access global markets faster. Navigating regulatory shifts like the TGA's proposal for greater transparency requires local expertise and a proactive strategy. We act as a local representative in Australia and over 30 other markets, providing continuous regulatory monitoring to keep you ahead of changes. Our experts and AI-powered tools streamline the creation of technical dossiers, manage post-market surveillance, and help you develop a robust strategy for compliance and market access. Contact us at info@pureglobal.com or visit https://pureglobal.com to learn more. Explore our free AI tools and regulatory database at https://pureglobal.ai.

  2. 1日前

    Health Canada Special Access Program: New Application Process for Medical Devices

    Health Canada has modernized the application process for its Medical Devices Special Access Program (SAP) as of August 24, 2026. This episode details the two key changes: the introduction of a new accessible PDF application form and a new secure online submission method. We explore Health Canada's goals to reduce errors, improve data security, and accelerate review times for unauthorized devices needed for patients with serious conditions, outlining the practical steps for healthcare professionals and manufacturers. Key Questions: - What is Health Canada's Special Access Program for medical devices? - What specific changes were announced for the SAP application process on August 24, 2026? - Why did Health Canada introduce a new PDF application form? - What are the benefits of the new secure online submission method? - Who is primarily affected by these SAP application changes? - How can manufacturers and healthcare professionals prepare for this new process? - What common errors is the new system designed to prevent? - What practical steps should regulatory teams take right now? Sources: - https://www.canada.ca/en/health-canada/services/drugs-health-products/medical-devices/announcements.html - https://www.smart-mdr.com/health-canada-announces-changes-to-special-access-program-application-process-for-medical-devices/ How Pure Global can help: Pure Global provides end-to-end regulatory consulting to help MedTech and IVD companies achieve faster global market access. We act as your local representative in over 30 markets, including Canada, developing efficient regulatory strategies and using advanced AI to compile and manage technical submissions. Our experts ensure ongoing compliance through post-market surveillance and continuous regulatory monitoring. For support with the Canadian SAP process or other market access challenges, contact us at info@pureglobal.com or visit https://pureglobal.com. Explore our free AI tools and extensive device database at https://pureglobal.ai.

  3. 2日前

    UK MHRA ResMed Astral Alert: Ventilator Safety Actions for NatPSA/2026/004/MHRA

    The UK's MHRA issued National Patient Safety Alert NatPSA/2026/004/MHRA on August 17, 2026, for ResMed Astral 100 and 150 ventilators manufactured before October 2024. A faulty internal supercapacitor can leak, causing the device to shut down unexpectedly and risking serious injury or death. This episode details the specific device fault, the risks to patients, and the mandatory actions required by the MHRA for healthcare providers and manufacturers. We focus on the critical importance of post-market surveillance and immediate risk mitigation for life-sustaining devices. Key Questions: - What is the specific defect in ResMed Astral ventilators identified by the MHRA? - Which device models and manufacturing dates are covered by NatPSA/2026/004/MHRA? - What are the immediate risks to patients in hospital and home care settings? - What actions must healthcare providers take to ensure patient safety? - How does this alert impact post-market surveillance obligations for manufacturers of life-sustaining devices? - What is the role of backup ventilation for affected patients? - How can teams document their response to this MHRA safety alert for compliance? - What lessons can be learned about component traceability and supplier quality management? Sources: - https://www.gov.uk/alerts-and-recalls/national-patient-safety-alert-resmed-astral-100-and-150-ventilators-potential-for-patient-harm-due-to-unexpected-interruption-of-ventilation-therapy-natpsa-2026-004-mhra - https://dispex.net/news-alerts/national-patient-safety-alert-resmed-astral-100-and-150-ventilators/ - https://www.gov.uk/government/publications/mhra-safety-roundup-august-2026/mhra-safety-roundup-august-2026 How Pure Global can help: Pure Global provides end-to-end regulatory consulting for MedTech companies, ensuring products meet safety and performance standards from development to post-market surveillance. Our experts help you establish robust post-market surveillance systems, manage incident reporting, and execute field safety corrective actions efficiently. With local representation in over 30 markets, including the UK, we act as your in-country contact with authorities like the MHRA, ensuring timely communication and compliance. Leverage our AI-powered tools and global database at https://pureglobal.ai to streamline your regulatory processes and maintain market access. Contact us at info@pureglobal.com or visit https://pureglobal.com to learn more.

  4. 3日前

    China NMPA Medical Device Approval: Analyzing the August 12, 2026 Batch

    China's NMPA announced the approval of 122 medical devices on August 12, 2026, including many from leading international manufacturers such as Medtronic, Roche, and Siemens. This episode breaks down this significant regulatory event, analyzing the types of devices approved—from cardiovascular and IVDs to imaging and surgical tools. We explore what this large batch of approvals reveals about the NMPA's current review priorities, the opportunities available for foreign manufacturers, and the practical steps your regulatory and market access teams should take to leverage these insights for a successful China strategy. Key Questions: - What does the NMPA's latest batch of 122 device approvals mean for the Chinese market? - Which types of medical devices are being prioritized by Chinese regulators? - How can foreign manufacturers like Medtronic and Siemens find success in China? - What do these approvals reveal about the NMPA's review timelines and pathways? - Are there new opportunities for cardiovascular, IVD, or imaging devices in China? - What practical steps should my regulatory team take in response to this news? - How can we leverage this information for our China market access strategy? - Does this signal a shift in China's policy towards imported medical devices? Sources: - https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQH02KbGyLdFMQfPN0_gVaWwc8YCTOtfEC-dbM5f0Jt-IBAMMrphnYEi5w8UKI1s8OoNRKu7vlRJ9ardRwtE9szhk3WH0WRsVoYrdgpq5qeq__bcflDwDPi7xcUqnvbxgL3S_3P1koNiqAyRZRhRR34= How Pure Global can help: Pure Global provides end-to-end regulatory consulting for MedTech and IVD companies seeking to access the Chinese market. Our in-country experts in China and advanced AI technology streamline the NMPA registration process, from developing a robust regulatory strategy and compiling technical dossiers to managing local type testing and post-market surveillance. We act as your local representative, ensuring seamless communication with the NMPA and helping you navigate complex requirements to get your product to market faster. To learn more about our China market access solutions, visit us at https://pureglobal.com, contact us at info@pureglobal.com, or explore our free AI tools and global device database at https://pureglobal.ai.

  5. 4日前

    Singapore HSA's New Medical Device Cybersecurity Guide (GL-10-R1): Key Principles and Actions

    Singapore's Health Sciences Authority (HSA) has released its finalized 'Best Practices Guide for Medical Device Cybersecurity' (GL-10-R1), effective August 17, 2026. This episode explores the guide's three core principles—secure-by-design, shared responsibility, and transparency—and outlines their impact on manufacturers and healthcare providers. We discuss how these recommendations affect the total product lifecycle, from pre-market design to post-market surveillance, and provide actionable steps for regulatory, quality, and market-access teams to align with these new expectations. Key Questions: - What is the scope of Singapore HSA's new cybersecurity guide, GL-10-R1? - When does the new guidance become effective? - How does the 'secure-by-design' principle impact device development? - What does 'shared responsibility' mean for manufacturers and healthcare providers? - Why is transparency, including the use of an SBOM, now a best practice in Singapore? - Is compliance with this guide mandatory for pre-market device registration? - What are the expectations for post-market cybersecurity surveillance? - How can our team perform a gap analysis against these new recommendations? - What documentation changes are needed to align with the HSA's TPLC approach? Sources: - https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGfeD51Gc0b8bXrqivrB1f_yGJ-oReepm1pwtUbCHvMVDMzBSGpP10xIL5VkgYs4NDhlHZU3XQ1R8FZ9pGI_k2Qf7XTrUr0r2h7hcYZTYd86gp2yGgNTzQG7bND_5OZSxuH2Wzf4ErQYG27cGNwR1hW2wJh75gaeyfNSCUJyTuDtr2TWgfKOs_-fS9Ws5c4juzk_x_xMeTh7-XsoDd3k-8EtMSXRuQIMVrXj2e-VHjgzzKeQGarhIAeSQCOpGA= - https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFxa4zvDJJCRocH1oHTSnh2B2AAAHJFDoujOt2pFVcWf4NqOVo-qqozSujWIfe4EneSoW2xdyqpEItPSjWNBRdQGjhhYBRGThO9JaIHCPHC1PWye_Db_zmovuHxhdoWWNbfB-L0mYtRE6HxFgqDWHgNBnc441qzL_QrqwExqXPJRQNH6dmtzg== How Pure Global can help: Pure Global provides end-to-end regulatory consulting for MedTech and IVD companies, helping you navigate complex requirements like Singapore's new cybersecurity guidance. We specialize in developing robust regulatory strategies, compiling and submitting technical dossiers, and implementing continuous regulatory monitoring to ensure your products remain compliant. Our combination of local expertise in over 30 markets and advanced AI technology streamlines the entire market access process, from initial gap analysis to post-market surveillance. For support with your global regulatory needs, visit us at https://pureglobal.com, contact us at info@pureglobal.com, or explore our free AI tools and regulatory database at https://pureglobal.ai.

  6. 5日前

    COFEPRIS Medical Device Sanitary Registry Viewer: What Manufacturers Need to Know

    Mexico's health authority, COFEPRIS, has launched the Medical Device Sanitary Registry Viewer, a public digital tool for verifying device registrations. This episode explores how this platform, launched on August 20, 2026, enhances market transparency and simplifies compliance. We discuss how the tool works, its impact on manufacturers, distributors, and healthcare providers, and outline practical steps for regulatory teams to adapt to this new environment. Key Questions: - What is the new COFEPRIS Medical Device Sanitary Registry Viewer? - How does this public database impact market transparency in Mexico? - What specific information can be found using the new digital tool? - How does the viewer help combat counterfeit or unregistered medical devices? - What are the implications for manufacturers holding sanitary registrations? - How should distributors and importers change their compliance processes? - What steps should regulatory teams take to verify their product portfolios? - How does this initiative fit into COFEPRIS's broader digitalization strategy? Sources: - https://mexicobusiness.news/health/news/cofepris-opens-public-viewer-for-medical-device-registries How Pure Global can help: Pure Global helps MedTech and IVD companies navigate complex regulatory landscapes like Mexico's. Our local experts and advanced AI tools streamline market access, from initial strategy and technical dossier submission to acting as your official Local Representative. We ensure your registrations remain compliant amidst changes like the new COFEPRIS digital viewer through continuous regulatory monitoring. Whether you're a startup or a multinational, we accelerate your path to market. Learn more about our services, free AI tools, and global database at https://pureglobal.ai, or contact us at info@pureglobal.com and https://pureglobal.com.

  7. 6日前

    India CDSCO Amends Sterilization Rules: What Removing the Loan Licence Means for Medical Devices

    India's CDSCO has amended the Medical Devices Rules, 2017, effective August 24, 2024, removing the 'loan licence' requirement for manufacturers who outsource device sterilization. This episode explains the amendment, details the new mandatory labeling requirements for sterilized products, and outlines the practical steps that regulatory and quality teams must take during the six-month transition period to ensure compliance. Key Questions: - What was the 'loan licence' requirement for medical device sterilization in India? - How does the CDSCO's August 2024 amendment change the rules for outsourced sterilization? - Who is most affected by this regulatory update? - What are the new, specific labeling requirements for sterile medical devices? - What is the deadline for manufacturers to comply with these new labeling rules? - How does this change impact the relationship between manufacturers and third-party sterilization facilities? - What practical steps should regulatory teams take to ensure compliance? - Does this amendment simplify the market access process in India? Sources: - https://www.livemint.com/industry/pharma/govt-eases-medical-device-rules-speeds-access-to-eu-approved-products-11724508681177.html How Pure Global can help: Pure Global offers end-to-end regulatory consulting for MedTech and IVD companies, streamlining global market access. For companies navigating changes like India's new sterilization rules, we provide expert regulatory strategy, technical dossier preparation, and local representation in over 30 markets. Our team helps ensure your labeling, QMS, and supplier agreements are fully compliant, minimizing delays and risks. Leverage our advanced AI tools and data-driven insights to manage submissions efficiently and maintain your market presence. Contact us at info@pureglobal.com or visit https://pureglobal.com. Explore our free AI tools and database at https://pureglobal.ai.

  8. 8月26日

    EU Notified Body Shake-Up: What the NSAI and TÜV NORD Exits Mean for MDR Certification

    The EU Notified Body landscape was shaken in August 2024 with announcements that the National Standards Authority of Ireland (NSAI) will exit its MDR designation by 2026 and TÜV NORD Scandinavia has filed for bankruptcy. This episode breaks down the immediate impact on manufacturers certified by these bodies, the broader implications for Notified Body capacity under the MDR, and the critical strategic steps regulatory teams must take now to protect their EU market access. Key Questions: - What were the specific announcements from NSAI and TÜV NORD Scandinavia in August 2024? - Why is the National Standards Authority of Ireland (NSAI) exiting the MDR business by 2026? - What led to the bankruptcy of TÜV NORD Scandinavia so soon after its acquisition? - If your device is certified by NSAI or TÜV NORD, what are your immediate obligations? - How does this reduction in Notified Bodies impact overall MDR certification capacity in the EU? - What are the key differences between an 'orderly exit' and a bankruptcy for a Notified Body? - What practical steps should regulatory teams take right now to secure their CE marking? - How can manufacturers vet the long-term stability of a potential new Notified Body partner? Sources: - https://medtech.citeline.com/MT153434/NSAI-Will-Make-Orderly-Exit-From-MDR-Notified-Body-Business - https://medtech.citeline.com/MT153424/Low-Demand-Causes-TV-NORD-Scandinavia-Bankruptcy-Just-7-Months-After-Purchase How Pure Global can help: Pure Global provides end-to-end regulatory consulting to help MedTech and IVD companies navigate complex market access challenges like unexpected Notified Body changes. Our experts can develop an immediate-response strategy, manage the complex process of transferring your CE certification to a new Notified Body, and ensure your technical documentation is prepared for a smooth transition. We act as your local representative and leverage advanced AI tools to streamline submissions and monitor regulatory shifts, ensuring your market presence is secure. Contact us at info@pureglobal.com or visit https://pureglobal.com to learn more. Explore our free AI regulatory tools and device database at https://pureglobal.ai.

番組について

Navigate every market. Accelerate every launch. Medical Device Global Market Access by Pure Global is the audio briefing that turns the world’s most confusing regulatory pathways into clear, actionable roadmaps. If you’re a MedTech founder, RA/QA leader, product manager, or investor who needs to get devices cleared anywhere from Austin to Abu Dhabi, this show is your shortcut. Why listen? • Step-by-step playbooks – We decode EU MDR, U.S. 510(k), Brazil’s ANVISA, China’s NMPA, and 25 + other regimes, showing exactly how long each milestone really takes and where companies get stuck. • First-hand war stories – Hear candid interviews with regulatory veterans who have shepherded implants, software, wearables, diagnostics, and AI algorithms to market—and lived to tell the tale. • Real-time intelligence – Every episode covering the week’s new guidances, standards, and enforcement trends so you’re always ahead of the curve. • Actionable templates – From clinical evaluation checklists to technical-file skeletons, we break down the documents you’ll need and the pitfalls reviewers love to flag. • AI-powered insights – Because Pure Global mines millions of public filings, tenders, and recalls, we surface data-backed best practices you won’t hear at conferences—or from competitors. What you’ll hear • Launching SaMD under multiple risk classes in parallel • Surviving an unannounced ISO 13485 audit • Building a “reg-first” QMS that scales • Mastering Latin-American registrations without endless language cycles • Leveraging real-world evidence to shorten clinical timelines • Aligning cybersecurity, privacy, and post-market surveillance rules across regions Whether you’re plotting first entry, managing lifecycle expansions, or rescuing a delayed submission, subscribing could shave months—and millions—off your path to revenue. ⸻ Brought to you by Pure Global – the AI-native consultancy that already guides MedTech innovators through regulatory and market-access hurdles in 30 + countries. Ready for expert help on your next submission? Visit https://pureglobal.com or email info@pureglobal.com to start accelerating today.

その他のおすすめ